Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 9/20 | 0.48 |
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880686 | 0.88 | PPARA (0.57) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL2118283 | 0.87 | CTSK (0.56) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL2118282 | 0.87 | CTSK (0.56) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL30788842 | 0.87 | CTSK (0.52) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL24335310 | 0.87 | CYP1A2 (0.49) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL24335172 | 0.87 | CYP1A2 (0.49) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL10832738 | 0.85 | CTSK (0.49) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL30788752 | 0.85 | CTSK (0.49) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL10832745 | 0.85 | CTSK (0.49) | CTSKCTSSPPARAPPARGCYP1A2 | |
| SCHEMBL3068814 | 0.84 | PPARA (0.60) | CTSKCTSSPPARAPPARGCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1546087-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | Abbott Laboratories (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004013085-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | ABBOTT LABORATORIES (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
| CN-1308608-A | Substituted beta-amino acid inhibitors of methionine aminopeptidase-2 | ABBOTT LAB (US) | 2001-08-15 | — | — | CN | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | CTSK 1816/4885CTSS 1360/4885PPARA 455/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | CTSK 2334/4885CTSS 1777/4885PPARA 4124/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | CTSK 2334/4885CTSS 1777/4885PPARA 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.